Summit Therapeutics, Inc. (SMMT)
13.84
+0.22
(+1.62%)
USD |
NASDAQ |
Sep 01, 11:12
Summit Therapeutics Cash from Operations (Annual) : -322.93M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -322.93M |
| December 31, 2024 | -142.11M |
| December 31, 2023 | -76.76M |
| December 31, 2022 | -41.58M |
| December 31, 2021 | -72.59M |
| December 31, 2020 | -48.11M |
| December 31, 2019 | -19.98M |
| January 31, 2019 | |
| January 31, 2018 | -19.08M |
| January 31, 2017 | 16.19M |
| January 31, 2016 | -26.09M |
| January 31, 2015 | -18.43M |
| Date | Value |
|---|---|
| January 31, 2014 | -9.184M |
| January 31, 2013 | -5.044M |
| January 31, 2012 | -3.863M |
| January 31, 2011 | -4.202M |
| January 31, 2010 | -4.970M |
| January 31, 2009 | -17.69M |
| January 31, 2008 | -14.68M |
| January 31, 2007 | -4.173M |
| January 31, 2006 | -1.648M |
| January 31, 2005 | 0.056M |
| January 31, 2004 | -0.1184M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| NovelStem International Corp. | -0.1676M |
| Brainstorm Cell Therapeutics, Inc. | -6.975M |
| Kezar Life Sciences, Inc. | -51.78M |
| Protara Therapeutics, Inc. | -56.36M |
| Clene, Inc. | -18.55M |